colistimethate sodium 1 million iu powder for nebuliser solution
noridem enterprises limited - colistimethate sodium - powder for nebuliser solution - colistin
colistimethate sodium 2 million iu powder for nebuliser solution
noridem enterprises limited - colistimethate sodium - powder for nebuliser solution - colistin
colistimethate sodium 1 million iu powder for solution for injection/infusion
noridem enterprises limited - colistimethate sodium - powder for solution for injection/infusion - colistin
colistimethate sodium 2 million iu powder for solution for injection/infusion
noridem enterprises limited - colistimethate sodium - powder for solution for injection/infusion - colistin
colistimethat-natrium noridem 1 million i.e. pulver zur herstellung einer injektions-/infusionslösung
colistimethat-natrium noridem 1 million i.e. pulver zur herstellung einer lösung für einen vernebler
colistimethat-natrium noridem 2 millionen i.e. pulver zur herstellung einer injektions-/infusionslösung
colistimethat-natrium noridem 2 millionen i.e. pulver zur herstellung einer lösung für einen vernebler
colistimethate- colistimethate sodium injection
x-gen pharmaceuticals, inc. - colistimethate (unii: dl2r53p963) (colistin - unii:z67x93hjg1) - colistin 150 mg in 2 ml - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or
colistimethate- colistimethate sodium injection
xellia pharmaceuticals aps - colistimethate (unii: dl2r53p963) (colistin - unii:z67x93hjg1) - colistin 150 mg in 2 ml - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or